199 related articles for article (PubMed ID: 28260010)
1. Astragaloside IV inhibits isoprenaline‑induced cardiac fibrosis by targeting the reactive oxygen species/mitogen‑activated protein kinase signaling axis.
Dai H; Jia G; Lu M; Liang C; Wang Y; Wang H
Mol Med Rep; 2017 Apr; 15(4):1765-1770. PubMed ID: 28260010
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cardiotrophin‑1 overexpression is involved in the anti‑fibrotic effect of Astrogaloside IV.
Jia G; Leng B; Wang H; Dai H
Mol Med Rep; 2017 Dec; 16(6):8365-8370. PubMed ID: 28990065
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB pathways.
Xu C; Tang F; Lu M; Yang J; Han R; Mei M; Hu J; Zhou M; Wang H
Int Immunopharmacol; 2016 Apr; 33():119-27. PubMed ID: 26903414
[TBL] [Abstract][Full Text] [Related]
4. Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.
Zhang S; Tang F; Yang Y; Lu M; Luan A; Zhang J; Yang J; Wang H
PLoS One; 2015; 10(3):e0118759. PubMed ID: 25738576
[TBL] [Abstract][Full Text] [Related]
5. [Effect of Combined Intervention of Electroacupuncture and Astragaloside IV on Myocardial Hypertrophy and TGF-β 1/Smad Signaling in Rats with Myocardial Fibrosis].
Li JS; Zhu XY; Lu ML; Gao JH; Wang HX; Yu XC
Zhen Ci Yan Jiu; 2017 Dec; 42(6):477-81. PubMed ID: 29318851
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway.
Wei Y; Wu Y; Feng K; Zhao Y; Tao R; Xu H; Tang Y
J Ethnopharmacol; 2020 Mar; 249():112404. PubMed ID: 31739105
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways.
Yin B; Hou XW; Lu ML
Acta Pharmacol Sin; 2019 May; 40(5):599-607. PubMed ID: 30030530
[TBL] [Abstract][Full Text] [Related]
8. Astragaloside IV suppresses inflammatory mediator production in synoviocytes and collagen‑induced arthritic rats.
Xu H; Wang CY; Zhang HN; Lv CY; Wang YZ
Mol Med Rep; 2016 Apr; 13(4):3289-96. PubMed ID: 26936538
[TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2/HO-1 Signaling Pathway.
Nie P; Meng F; Zhang J; Wei X; Shen C
Oxid Med Cell Longev; 2019; 2019():4625912. PubMed ID: 31285785
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV attenuates penicillin-induced epilepsy via inhibiting activation of the MAPK signaling pathway.
Zhu X; Chen Y; Du Y; Wan Q; Xu Y; Wu J
Mol Med Rep; 2018 Jan; 17(1):643-647. PubMed ID: 29115438
[TBL] [Abstract][Full Text] [Related]
11. Danshensu inhibits β-adrenergic receptors-mediated cardiac fibrosis by ROS/p38 MAPK axis.
Lu H; Tian A; Wu J; Yang C; Xing R; Jia P; Yang L; Zhang Y; Zheng X; Li Z
Biol Pharm Bull; 2014; 37(6):961-7. PubMed ID: 24882408
[TBL] [Abstract][Full Text] [Related]
12. Effect of astragaloside IV against rat myocardial cell apoptosis induced by oxidative stress via mitochondrial ATP-sensitive potassium channels.
Guan FY; Yang SJ; Liu J; Yang SR
Mol Med Rep; 2015 Jul; 12(1):371-6. PubMed ID: 25739067
[TBL] [Abstract][Full Text] [Related]
13. A metabolite of Danshen formulae attenuates cardiac fibrosis induced by isoprenaline, via a NOX2/ROS/p38 pathway.
Yin Q; Lu H; Bai Y; Tian A; Yang Q; Wu J; Yang C; Fan TP; Zhang Y; Zheng X; Zheng X; Li Z
Br J Pharmacol; 2015 Dec; 172(23):5573-85. PubMed ID: 25766073
[TBL] [Abstract][Full Text] [Related]
14. Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling.
Luo LF; Guan P; Qin LY; Wang JX; Wang N; Ji ES
Mol Cell Biochem; 2021 Jul; 476(7):2603-2611. PubMed ID: 33656642
[TBL] [Abstract][Full Text] [Related]
15. Quercetin inhibition of myocardial fibrosis through regulating MAPK signaling pathway via ROS.
Min Z; Yangchun L; Yuquan W; Changying Z
Pak J Pharm Sci; 2019 May; 32(3 Special):1355-1359. PubMed ID: 31551215
[TBL] [Abstract][Full Text] [Related]
16. Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions.
Sun L; Li W; Li W; Xiong L; Li G; Ma R
Int J Mol Med; 2014 Jul; 34(1):167-76. PubMed ID: 24718766
[TBL] [Abstract][Full Text] [Related]
17. Astragaloside IV prevents high glucose‑induced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells.
You L; Fang Z; Shen G; Wang Q; He Y; Ye S; Wang L; Hu M; Lin Y; Liu M; Jiang A
Mol Med Rep; 2019 Mar; 19(3):1603-1612. PubMed ID: 30628687
[TBL] [Abstract][Full Text] [Related]
18. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy.
Yang J; Wang HX; Zhang YJ; Yang YH; Lu ML; Zhang J; Li ST; Zhang SP; Li G
J Ethnopharmacol; 2013 Dec; 150(3):1062-70. PubMed ID: 24432369
[TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV protects against the pathological cardiac hypertrophy in mice.
Liu ZH; Liu HB; Wang J
Biomed Pharmacother; 2018 Jan; 97():1468-1478. PubMed ID: 29793309
[TBL] [Abstract][Full Text] [Related]
20. Astragaloside IV downregulates the expression of MDR1 in Bel‑7402/FU human hepatic cancer cells by inhibiting the JNK/c‑Jun/AP‑1 signaling pathway.
Wang PP; Luan JJ; Xu WK; Wang L; Xu DJ; Yang CY; Zhu YH; Wang YQ
Mol Med Rep; 2017 Sep; 16(3):2761-2766. PubMed ID: 28713943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
